Publikation

Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland.

Wissenschaftlicher Artikel/Review - 09.02.2023

Çakar Esra, Oniangue-Ndza César, Schneider Ralph P, Klijn Sven L, Vogl Ursula M, Rothermundt Christian, May Jessica R